Abstract |
Thirty patients with evidence of hypometabolism or a clinically related condition were given triiodothyronine after suboptimal response to thyroxin or desiccated thyroid. DL- and L-isomers of triiodothyronine were used and compared. Thirteen patients (43.3 per cent) were improved and 17 (56.6 per cent) were unimproved or became worse. Side effects occurred in 9 of 34 trials (26 per cent), and could not always be eliminated by decreasing the dosage. The highest percentage of good response occurred in a small group (four of five) who received a combination of desiccated thyroid or thyroxin with supplemental triiodothyronine. Despite careful analysis of the data, no basis was found on which to predict which patients would receive benefit from the triiodothyronine. However, the occasional improvement, sometimes dramatic, suggested that a therapeutic trial with triiodothyronine in difficult or unresponsive cases of hypometabolism or hypothyroidism is justified.
|
Authors | S NEWMAN, R F ESCAMILLA |
Journal | California medicine
(Calif Med)
Vol. 88
Issue 3
Pg. 206-10
(Mar 1958)
ISSN: 0008-1264 [Print] United States |
PMID | 13511212
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Triiodothyronine
- Thyroxine
|
Topics |
- Antineoplastic Agents, Hormonal
- Basal Metabolism
- Humans
- Hypothyroidism
(therapy)
- Thyroxine
- Triiodothyronine
(therapeutic use)
|